Skip to main content

Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

Trial Status: Active

A phase I trial to evaluate the safety and tolerability of ALS-357 when administered for four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic melanoma and to evaluate the effect of escalating doses of topically applied ALS-357 on histological remission of cutaneous metastatic melanoma and induction of apoptotic biomarkers.

Inclusion Criteria

  • Inclusion Criteria: - Study Participants must be 18 years or older. - Study Participants must have 2 sites of cutaneous metastatic melanoma that can not be removed with surgery. - Study Participants may have been previously treated with chemotherapy or immunotherapy but not with in 4 weeks of first dose of study treatment.


Northwestern University

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Advanced Life Sciences

  • Primary ID ALS-357-001
  • Secondary IDs NCI-2010-01853
  • ID NCT00701987